Values First Advisors Inc. Purchases 3,777 Shares of Guardant Health, Inc. (NASDAQ:GH)

Values First Advisors Inc. grew its stake in Guardant Health, Inc. (NASDAQ:GH) by 13.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,025 shares of the company’s stock after purchasing an additional 3,777 shares during the period. Values First Advisors Inc.’s holdings in Guardant Health were worth $735,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $44,000. Canton Hathaway LLC acquired a new stake in Guardant Health during the 2nd quarter worth approximately $59,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Guardant Health during the 2nd quarter worth approximately $71,000. Byrne Asset Management LLC acquired a new stake in Guardant Health during the 2nd quarter worth approximately $77,000. Finally, Manchester Capital Management LLC acquired a new stake in Guardant Health during the 1st quarter worth approximately $57,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GH. Bank of America raised their price target on shares of Guardant Health from $28.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 18th. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 17th. Craig Hallum lifted their price objective on shares of Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Finally, BTIG Research boosted their price target on shares of Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $40.31.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $20.20 on Friday. The company’s 50-day moving average is $23.88 and its 200 day moving average is $25.50. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40. The company has a market capitalization of $2.47 billion, a P/E ratio of -5.15 and a beta of 1.11. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $37.04.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The company had revenue of $177.24 million during the quarter, compared to analysts’ expectations of $162.59 million. Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. Guardant Health’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.67) earnings per share. On average, equities research analysts forecast that Guardant Health, Inc. will post -3.31 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.